Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2026-04-27 @ 6:25 PM
Study NCT ID:
NCT04726033
Status:
COMPLETED
Last Update Posted:
2024-05-01
First Post:
2020-10-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
Sponsor:
Telix Pharmaceuticals (Innovations) Pty Limited
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
64Cu-TLX592-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None